The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
Abstract
Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as hypomethylation agents (HMAs), can enhance the antitumor immune response by inducing TAA expression. Here, a dual bioresponsive gel depot that can respond to the acidic pH and reactive oxygen species (ROS) within the tumor microenvironment (TME) for codelivery of anti‐PD1 antibody (aPD1) and Zebularine (Zeb), an HMA, is engineered. aPD1 is first loaded into pH‐sensitive calcium carbonate nanoparticles (CaCO 3 NPs), which are then encapsulated in the ROS‐responsive hydrogel together with Zeb (Zeb‐aPD1‐NPs‐Gel). It is demonstrated that this combination therapy increases the immunogenicity of cancer cells, and also plays roles in reversing immunosuppressive TME, which contributes to inhibiting the tumor growth and prolonging the survival time of B16F10‐melanoma‐bearing mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [27]
Citations
Cites
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,612
Self-citationAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,455
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,414
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,347
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lü, Y., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,029
Self-citationDe Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G. A. M., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 808
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 602
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H. N., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Self-citationThe activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
Smet, C. D., Backer, O. D., Faraoni, I., Lurquin, C., Brasseur, F., & Boon, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7149 · Cited by 542
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Márquez, V. E., Jones, P. A., & Selker, E. U. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.399 · Cited by 532
Boyerinas, B., Jochéms, C., Fantini, M. C., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 476
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428
Control of muscle formation by the fusogenic micropeptide myomixer
Bi, P., Ramirez-Martinez, A., Li, H. Z., Cannavino, J., McAnally, J., Shelton, J. M., Sanchez‐Ortiz, E., Bassel‐Duby, R., & Olson, E. N. (2017) · Science · doi:10.1126/science.aam9361 · Cited by 419
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J. M., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F. P., Criekinge, W. V., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 389
The MAGE proteins: Emerging roles in cell cycle progression, apoptosis, and neurogenetic disease
Barker, P. A., & Salehi, A. H. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10160 · Cited by 320
DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.
Gnyszka, A., Jastrzębski, Z., & Flis, S. (2013) · PubMed · Cited by 309
Core–Shell Microneedle Gel for Self-Regulated Insulin Delivery
Wang, J., Ye, Y., Yu, J., Kahkoska, A. R., Zhang, X., Wang, C., Sun, W., Corder, R. D., Chen, Z., Khan, S. A., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08152 · Cited by 299
Self-citationWang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., & Rosenberg, S. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.2.799 · Cited by 270
Converting Cold into Hot Tumors by Combining Immunotherapies
Haanen, J. B. A. G. (2017) · Cell · doi:10.1016/j.cell.2017.08.031 · Cited by 266
Reactivating the expression of methylation silenced genes in human cancer
Karpf, A. R., & Jones, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205602 · Cited by 264
Lee, J.-M., Cimino‐Mathews, A., Peer, C. J., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 243
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194
Wang, L., Amoozgar, Z., Huang, J., Saleh, M. H., Xing, D., Orsulic, S., & Goldberg, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0073 · Cited by 173
Yu, J., Ni, M., Xu, J., Zhang, H., Gao, B., Gu, J., Chen, J., Zhang, L., Wu, M., Zhen, S., et al. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-29 · Cited by 170
Yu, J., Zhang, H., Gu, J. F., Lin, S., Li, J., Lu, W., Wang, Y., & Zhu, J. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-65 · Cited by 122
Self-citationEpigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b
James, S. R., Link, P. A., & Karpf, A. R. (2006) · Oncogene · doi:10.1038/sj.onc.1209678 · Cited by 120
Rao, M., Chinnasamy, N., Hong, J. A., Zhang, Y., Zhang, M. F., Xi, S., Liu, F., Márquez, V. E., Morgan, R. A., & Schrump, D. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2442 · Cited by 113
Kakizawa, Y., & Kataoka, K. (2002) · Langmuir · doi:10.1021/la011736s · Cited by 106
Yoo, C. B., Chuang, J. C., Byun, H., Egger, G., Yang, A. S., Dubeau, L., Long, T. I., Laird, P. W., Márquez, V. E., & Jones, P. A. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-07-0008 · Cited by 102
Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy
Márquez, V. E., Kelley, J. A., Agbaria, R., BEN‐KASUS, T., Cheng, J., Yoo, C. B., & Jones, P. A. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1359.037 · Cited by 100
Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers
Ruan, H., Chen, X., Xie, C., Li, B., Man, Y. M., Liu, Y., Zhang, M., Zhang, X., Zhan, C., Lu, W., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03682 · Cited by 90
Self-citationWargo, J. A., Robbins, P. F., Li, Y., Zhao, Y., El‐Gamil, M., Caragacianu, D. L., Zheng, Z., Hong, J. A., Downey, S. G., Schrump, D. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0562-x · Cited by 87
Neureiter, D., Zopf, S., Leu, T., Dietze, O., Hauser‐Kronberger, C., Hahn, E. G., Herold, C., & Ocker, M. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520600874198 · Cited by 77
Sasaki, M., Nakahira, K., Kawano, Y., Katakura, H., Yoshimine, T., Shimizu, K., Kim, S. U., & Ikenaka, K. (2001) · PubMed · Cited by 62
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis
Leslie, M. C., Zhao, Y.-J., Lachman, L. B., Hwu, P., & Bar‐Eli, M. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302864 · Cited by 59
Terracina, K. P., Graham, L., Payne, K. K., Manjili, M. H., Baek, A. E., Damle, S., & Bear, H. D. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1868-8 · Cited by 55
Toor, A. A., Payne, K. K., Chung, H. M., Sabo, R., Hazlett, A. F., Kmieciak, M., Sanford, K., Williams, D. C., Clark, W., Roberts, C. H., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09225.x · Cited by 44
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Ruan, H., Bu, L., Hu, Q., Cheng, H., Lu, W., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801099 · Cited by 40
Self-citationTriozzi, P. L., Aldrich, W. A., Achberger, S., Ponnazhagan, S., Alcazar, O., & Saunthararajah, Y. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1204-x · Cited by 38
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara, F. (2013) · Hematological Oncology · doi:10.1002/hon.2046 · Cited by 34
Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression
Serrano, A., Castro-Vega, I., & Redondo, M. (2011) · Cancers · doi:10.3390/cancers3021672 · Cited by 28
Almasri, J., Alkhateeb, H. B., Firwana, B., Sonbol, M. B., Damlaj, M., Wang, Z., Murad, M. H., & Al‐Kali, A. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0805-7 · Cited by 20
Azacitidine in AML: a treatment option?
Huls, G. A. (2015) · Blood · doi:10.1182/blood-2015-06-648071 · Cited by 17
Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
Morfouace, M., Nimmervoll, B. V., Boulos, N., Patel, Y. T., Shelat, A. A., Freeman, B. B., Robinson, G. W., Wright, K. D., Gajjar, A. J., Stewart, C. F., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1965-0 · Cited by 14
Research works printed but not linked: 4
- Héninger E., 2015, Front. Immunol., 6, 29
- Gnyszka A., 2013, Anticancer Res., 33, 2989
- Sasaki M., 2001, Cancer Res., 61, 4809
- Nishiyama N., 2003, Cancer Res., 63, 8977
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Hernandez, H. L., Chan, D. C., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,174
Calcium carbonate: controlled synthesis, surface functionalization, and nanostructured materials
Niu, Y., Liu, J., Aymonier, C., Fermani, S., Kralj, D., Falini, G., & Zhou, C. H. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00519g · Cited by 435
An intrinsically bioactive hydrogel with on-demand drug release behaviors for diabetic wound healing
Hu, B., Gao, M., Boakye‐Yiadom, K. O., Ho, W., Yu, W., Xu, X., & Zhang, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.040 · Cited by 311
Smart Injectable Hydrogels for Cancer Immunotherapy
Chao, Y., Chen, Q., & Liu, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201902785 · Cited by 274
Self-citation
Metadata
- Authors
- Ruan, H., Hu, Q., Wen, D., Chen, Q., Chen, G., Lu, Y., Wang, J., Cheng, H., Lu, W., & Gu, Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Department of Bioengineering University of California Los Angeles CA 90095 USA
- Drexel University (US)
- Fudan University (CN)
- Corresponding author
- Lu, Weiyue
- Gu, Zhen
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-03-11
- Volume
- 31
- Issue
- 17
- Pages
- e1806957-e1806957
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2922000375
- Cited by
- 220
- References
- 55
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 31 · 2023: 32 · 2022: 40 · 2021: 38 · 2020: 39 · 2019: 17
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of North Carolina at Chapel Hill
- Alfred P. Sloan Foundation
- National Natural Science Foundation of China (81690263)
- China Scholarship Council
- Topics
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- advanced melanoma, epigenetic modulation, zebularine, PD-1/PD-L1 blockade, anti-PD-1, ROS-responsive hydrogel, tumor microenvironment, tumor-associated antigen expression, immunosuppressive tumor microenvironment, combination immunotherapy, B16F10 melanoma
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Calcium Carbonate, Cytidine, Drug Therapy, Combination, Humans, Hydrogen-Ion Concentration, Immunosuppressive Agents, Immunotherapy, Melanoma, Drug Delivery Systems, Reactive Oxygen Species, Cell Line, Tumor, Nanoparticles, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
